Insilico announces positive results from Phase I trials of AI-designed ISM5411
Hong Kong-based Insilico Medicine has announced positive results from two Phase I studies of ISM5411 (NCT06012578), a novel gut-restricted and…
Hong Kong-based Insilico Medicine has announced positive results from two Phase I studies of ISM5411 (NCT06012578), a novel gut-restricted and…
New analysis of real-world data from the largest US Lyme disease registry, MyLymeData, has shown that most persistent Lyme disease…
Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing…
Early signals from an ongoing study at the Christie Hospital in Manchester shore up the evidence for an investigational treatment…
Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery…
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity…
Clinical-stage biotechnology company Marengo Therapeutics has announced that it has dosed the first patient in Phase II of its STARt-001…
The RH5.1/Matrix-M blood-stage vaccine could constitute a crucial secondary defence for communities at high risk of malaria infection, including those…
The Asia-Pacific (APAC) region is leading in the Parkinson’s disease clinical trial space globally with 44% of trials, according to…
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced that it is providing up to $9.9m for a vaccine safety…